Within a report performed by the Cancer and Leukemia Group B in advanced lung cancer cutting phase.

CYFRA reliable marker for response to chemotherapy for NSCLC Researchers found that CYFRA and modification in levels of CYFRA were found to end up being reliable markers for response to chemotherapy for non-small cell lung malignancy in a study of 88 patients. Study shown in the April 2012 problem of the International Association for the Study of Lung Cancer’s Journal of Thoracic Oncology implies that this marker can be used to determine whether or not a patient should continue a specific chemotherapy regimen cutting phase .

mild impact

For the entire year ended December 31, 2011, the decrease in net loss due to common shareholders is due to a decrease in selling mainly, administrative and general expenditures, a $11.0 million gain related to a litigation settlement and decrease in non-cash considered dividends on favored stock issuances. Latest Highlights In February 2012, the European Medications Agency’s Committee for Human Medicinal Items granted a positive opinion for conditional authorization of CTI’s marketing authorization software for Pixuvri to take care of adult sufferers with multiple relapsed or refractory intense non-Hodgkin B-cell lymphomas . Related StoriesFDA grants accelerated authorization for Tagrisso to take care of individuals with advanced NSCLCNew RNA check of blood platelets can be used to identify area of cancerMD Anderson study reveals why chemotherapy drugs not effective for many pancreatic cancer patients’We expect that in the next couple of months the European Commission should adopt the CHMP’s opinion for this unmet medical want and for the 1st time individuals with multiple relapsed or refractory intense NHL in the E.U.